Urolithin A During Bedrest in Older Adults

This study will determine whether oral urolithin A (UA) attenuates the loss of knee-extensor strength caused by 10 days of horizontal bed rest in older adults.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The randomized comparison will also assess muscle mass, cardiorespiratory fitness, physical performance and glucose tolerance, together with cellular mechanisms of muscle adaptation. Orthostatic tolerance, balance responses to galvanic vestibular stimulation (GVS), salivary cortisol, and oral and fecal microbiome profiles will provide complementary exploratory measures of adaptation and recovery.v

Study Type

Interventional

Enrollment (Estimated)

48

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Sharmila Research Coordinator Baccalaureate Nurse
  • Phone Number: 1+514-984-9975
  • Email: reachlab@muhc.mcgill.ca

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years to 90 years (Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Men and women at least 65 years of age at enrolment, with a recruitment target of equal numbers of each sex
  • English or French speaking
  • Females not of childbearing potential
  • Willing to maintain current lifestyle and dietary habits, including level of physical activity, allowed medication/supplements habits for the duration of the study
  • Physically inactive, defined for eligibility as reporting no more than 2.5 hours of moderate-to-vigorous physical activity per week.

Exclusion Criteria:

  • Participated in a clinical trial within 90 days of screening or more than 4 times in the previous year.
  • Neuropsychological condition and/or cognitive impairment that, in the QI's opinion, could interfere with study participation.
  • Uncontrolled hypothyroidism or hyperthyroidism. Hypothyroid patients who have changed their dose of hormone replacement therapy in the 6 weeks before screening are not eligible.
  • Confirmed rheumatoid arthritis, acquired immunodeficiency syndrome (AIDS), type 1 or type 2 diabetes mellitus.
  • History of cancer in the last 6 months.
  • On any medications including NHPs/living with medical conditions that would compromise the study outcome or the safety of the research participant. For any supplements deemed acceptable, participants must be on a stable dose of allowed supplements/medications for at least 3 months prior to enrollment. All concomitant therapies will be documented.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Bed rest-Urolithin A group (BR-UA)

Participants in BR-UA group will receive a total of 1,000 mg of UA orally each day.

1000mg Urolithin A daily

Other Names:
  • Mitopure
Placebo Comparator: BR-PLA group (C)

Participants in group "C" will receive matching placebo.

Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in knee extensor strength using biodex at baseline and following the intervention.
Time Frame: Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)

To determine whether UA supplementation reduces the percentage loss of maximal voluntary isometric knee-extensor strength (N) using Biodex between baseline and recovery, compared with placebo.

Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)
Changes in V02 using indirect calorimetry at baseline and following the intervention.
Time Frame: Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)

To compare the effects of UA and placebo on cardiorespiratory fitness function using peak oxygen uptake (VO2peak) between baseline and recovery, compared with placebo.

Between baseline testing (B2) and after 10 days of bedrest during the recovery period (R3)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in body composition using DEXA scan at baseline and following the intervention.
Time Frame: Between baseline testing (B1) and after 10 days of bedrest during the recovery period (R3)

To determine whether UA supplementation had an effect on changes in fat free mass and fat mass using the DEXA scan between baseline and recovery, compared with placebo.

Between baseline testing (B1) and after 10 days of bedrest during the recovery period (R3)
Changes in mitochondrial respiration at baseline and following the intervention.
Time Frame: Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R3)

To determine whether UA supplementation had an effect on changes in mitochondrial respiration and function using the OROBORUS from muscle biopsy samples between baseline and recovery, compared with placebo.

Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R3)
Changes in muscle mass at baseline and following the intervention.
Time Frame: Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R2)

To determine whether UA supplementation had an effect on changes in muscle mass using CT scan between baseline and recovery, compared with placebo.

Between baseline testing (B3) and after 10 days of bedrest during the recovery period (R2)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Jose A Morais, Medical Doctor, McGill University Health Centre/Research Institute of the McGill University Health Centre

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 1, 2027

Primary Completion (Estimated)

August 1, 2031

Study Completion (Estimated)

August 1, 2031

Study Registration Dates

First Submitted

November 2, 2026

First Submitted That Met QC Criteria

November 17, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2027-13109

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.